International Agency for Research on Cancer (IARC) - Summaries & Evaluations

(Group 2B)

For definition of Groups, see Preamble Evaluation.

Supplement 7:: (1987) (p. 391)

CAS No.: 126-07-8
Chem. Abstr. Name: 2-S-trans)-7-Chloro-2',4,6-trimethoxy-6'-methylspiro[benzofuran-2(3H),1'-(2)-cyclohexene]-3,4'-dione

A. Evidence for carcinogenicity to animals (sufficient)

Griseofulvin induced liver tumours following its oral administration to adult mice [ref: 1-3] or its subcutaneous administration to infant male mice [ref: 1]. When given orally to rats and hamsters, it produced a significant increase in the incidence of thyroid tumours in rats but had no carcinogenic effect in hamsters [ref: 2].

Overall evaluation

Griseofulvin is possibly carcinogenic to humans (Group 2B).

For definition of the italicized terms, see Preamble Evaluation.

Subsequent evaluation: Vol. 79 (2001)

Also see previous evaluation: Vol. 10 (1976)


1. IARC Monographs, 10, 153-161, 1976

2. Rustia, M. & Shubik, P. (1978) Thyroid tumours in rats and hepatomas in mice after griseofulvin treatment. Br. J. Cancer, 38, 237-249

3. Chlumská, A.A. & Janousek, V. (1981) Hepatomas after long-term administration of griseofulvin (Czech.). Cesk. Patol., 17, 83-87


Last Updated: 2 March 1998

    See Also:
       Toxicological Abbreviations
       Griseofulvin  (IARC Summary & Evaluation, Supplement7, 1987)
       Griseofulvin  (IARC Summary & Evaluation, Volume 10, 1976)
       Griseofulvin  (IARC Summary & Evaluation, Volume 79, 2001)